Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Iron recommendations

This article was originally published in The Tan Sheet

Executive Summary

Asymptomatic pregnant women should be routinely screened for iron deficiency anemia, according to new recommendations issued by the U.S. Preventive Services Task Force. Organized by the Agency for Healthcare Research & Quality, the USPSTF "found fair evidence that treating symptomatic pregnant women who have iron deficiency anemia results in moderate benefits in health outcomes." The Task Force also recommends "routine iron supplementation for asymptomatic children aged six to 12 months who are at increased risk for iron deficiency anemia." Both recommendations are rated to be of "B" grade, meaning that the USPSTF recommends clinicians provide this information to patients. However, due to "insufficient evidence," the USPSTF was unable to recommend for or against screening for iron deficiency anemia and/or iron supplementation in asymptomatic children, as well as for or against supplementation in non-anemic pregnant women...

You may also be interested in...

Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions

Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Canada Explains Studies Needed For Subsequent-Entry Orally Inhaled Products

A new draft guideline explains how sponsors of subsequent-entry orally inhaled drug products can comply with the Canadian requirement for demonstrating equivalence to the reference product.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts